Neuren Pharmaceuticals - Drug NNZ-2591 for Phelan-McDermid syndrome
Update: 2024-03-22
Description
This month we feature three representatives from Neuren Pharmaceuticals to answer frequently asked questions about the recent Phase 2 clinical trial, and plans for a Phase 3. Larry Glass, Neuren’s Chief Science Officer provides an insightful breakdown of NNZ-2591, the drug that was being tested. Additionally, Liza Squires, Chief Medical Officer, and Nancy Jones, VP of Clinical Development, offer an overview of the safety, tolerability, and efficacy results.
Important links:
Phase 2 top line results:
Phase 2 inclusion and exclusion criteria
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
